Standardizing eligibility and patient selection for Pressurized Intraperitoneal Aerosol Chemotherapy: A Delphi consensus statement.
Details
Serval ID
serval:BIB_A540062EF6A7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Standardizing eligibility and patient selection for Pressurized Intraperitoneal Aerosol Chemotherapy: A Delphi consensus statement.
Journal
European journal of surgical oncology
Working group(s)
INPACT study group
Contributor(s)
Afifi A., Alyami M., Mortensen M.B., Bhatt A., Brandl A., Brigand C., Casella F., Chia C.S., Coget J., Delgadillo X., Dellinger T., Di Giorgio A., Escayola C., Ezanno A.C., Geboes K., Giger-Pabst U., Gockel I., Graversen M., Jäger T., Jones S., Katdare N., Kepenekian V., Khomiakov V., Kothonidis K., Lavoue V., Lehmann K., Lordick F., Lynch C., Mulier S., Paquette B., Yong W.P., Prenen H., Raoof M., Rau B., Ris F., Robella M., Somashekhar S.P., Sourrouille I., Steffen T., Sundar R., Thieme R., Torkington J., Ukegjini K., Van der Speeten K., Villeneuve L.
ISSN
1532-2157 (Electronic)
ISSN-L
0748-7983
Publication state
Published
Issued date
06/2024
Peer-reviewed
Oui
Volume
50
Number
6
Pages
108346
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a procedure for minimally invasive drug administration in patients with peritoneal metastasis. Previous studies have emphasized the importance of uniformity in treatment protocols and standardization of this practice. This study aimed to reach a consensus on eligibility, patient selection, and choice of chemotherapy for PIPAC.
A three-round modified Delphi study was conducted. A steering group formulated a list of baseline statements, addressing the objectives. The steering group consisted of seven expert surgical and medical oncologists. Available evidence and published key opinions were critically reviewed. An international expert panel scored those statements on a 4-point Likert scale. The statements were submitted electronically and anonymously. Consensus was reached if the agreement rate was ≥75%. A minimum Cronbach's alpha of >0.8 was set.
Forty-five (45/58; 77.6%) experts participated and completed all rounds. Experts were digestive surgeons (n = 28), surgical oncologists (n = 7), gynecologists (n = 5), medical oncologists (n = 4), and one clinical researcher. Their assessment of 81 preliminary statements in the first round resulted in 41 consolidated statements. In round two, consensus was reached on 40 statements (40/41; 97.6%) with a consensus of ≥80% for each individual statement. In the third round, 40 statements were unanimously approved as definitive. The choice of first- and second-line chemotherapy remained controversial and could not reach consensus.
This International Delphi study provides practical guidance on eligibility and patient selection for PIPAC. Ongoing trial data and long-term results that could contribute to the further standardization of PIPAC are eagerly awaited.
A three-round modified Delphi study was conducted. A steering group formulated a list of baseline statements, addressing the objectives. The steering group consisted of seven expert surgical and medical oncologists. Available evidence and published key opinions were critically reviewed. An international expert panel scored those statements on a 4-point Likert scale. The statements were submitted electronically and anonymously. Consensus was reached if the agreement rate was ≥75%. A minimum Cronbach's alpha of >0.8 was set.
Forty-five (45/58; 77.6%) experts participated and completed all rounds. Experts were digestive surgeons (n = 28), surgical oncologists (n = 7), gynecologists (n = 5), medical oncologists (n = 4), and one clinical researcher. Their assessment of 81 preliminary statements in the first round resulted in 41 consolidated statements. In round two, consensus was reached on 40 statements (40/41; 97.6%) with a consensus of ≥80% for each individual statement. In the third round, 40 statements were unanimously approved as definitive. The choice of first- and second-line chemotherapy remained controversial and could not reach consensus.
This International Delphi study provides practical guidance on eligibility and patient selection for PIPAC. Ongoing trial data and long-term results that could contribute to the further standardization of PIPAC are eagerly awaited.
Keywords
Humans, Delphi Technique, Patient Selection, Aerosols, Peritoneal Neoplasms/drug therapy, Peritoneal Neoplasms/secondary, Consensus, Antineoplastic Agents/administration & dosage, Infusions, Parenteral, Eligibility Determination, Expert consensus, Guidelines, Indications, PIPAC, Peritoneal metastases, Treatment protocol
Pubmed
Web of science
Create date
03/05/2024 15:27
Last modification date
14/06/2024 6:02